Goldman Sachs’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.9M | Buy |
|
|||||
|
2025
Q1 | $16.8M | Sell |
|
|||||
|
2024
Q4 | $36.9M | Sell |
|
|||||
|
2024
Q3 | $40.2M | Buy |
|
|||||
|
2024
Q2 | $29.1M | Sell |
|
|||||
|
2024
Q1 | $40.4M | Buy |
|
|||||
|
2023
Q4 | $23.1M | Buy |
|
|||||
|
2023
Q3 | $16.4M | Sell |
|
|||||
|
2023
Q2 | $11.1M | Buy |
|
|||||
|
2023
Q1 | $8.35M | Buy |
|
|||||
|
2022
Q4 | $2.44M | Buy |
|
|||||
|
2022
Q3 | $2.41M | Buy |
|
|||||
|
2022
Q2 | $1.82M | Sell |
|
|||||
|
2022
Q1 | $2.43M | Buy |
|
|||||
|
2021
Q4 | $1.75M | Buy |
|
|||||
|
2021
Q3 | $1.17M | Sell |
|
|||||
|
2021
Q2 | $1.15M | Sell |
|
|||||
|
2021
Q1 | $1.87M | Sell |
|
|||||
|
2020
Q4 | $1.81M | Buy |
|
|||||
|
2020
Q3 | $1.59M | Buy |
|
|||||
|
2020
Q2 | $246K | Buy |
|
|||||
|
2019
Q4 | – | Sell |
|
|||||
|
2019
Q3 | $1.09M | Sell |
|
|||||
|
2019
Q2 | $4.53M | Buy |
|
|||||
|
2019
Q1 | $328K | Buy |
|
|||||
|
2018
Q4 | $329K | Buy |
|